

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Glucose B. Braun Vet Care 50 mg/ml solution for infusion for cattle, horses, sheep, goats, pigs, dogs and cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Glucose 50.0 mg
(equivalent to glucose monohydrate 55.0 mg)

Excipient:

Qualitative composition of excipients and other constituent
--

Water for injections

Caloric value 837 kJ/l = 200 kcal/l
Theoretical osmolarity 278 mOsm/l
pH value 3.5 - 5.5

Clear, colourless or almost colourless aqueous solution, free from visible particles.

3. CLINICAL INFORMATION

3.1 Targets species

Cattle, horses, sheep, goats, pigs, dogs and cats

3.2 Indications for use for each targets species

- Treatment of dehydration (in the absence of shock)
- Parenteral rehydration
- Correction of hypernatremia
- Correction of hyperkalaemia
- Transient supportive treatment of hypoglycaemia

3.3 Contraindications

Do not use in animals with hyperglycaemia.

Do not use for the correction of hypotonic dehydration.

Do not use in animals with pre-existing peripheral oedema caused by a reduction in intravascular oncotic pressure.

This veterinary medicinal product is not suitable as a sole source of calorie requirements or as a substitute for oral or parenteral nutrition.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

This veterinary medicinal product does not contain electrolytes. Care should be taken to closely monitor electrolyte and phosphate balance in patients undergoing infusion of this product, and to adjust treatment accordingly.

This veterinary medicinal product should be used with particular caution in animals with the following conditions:

- Diabetes mellitus
- Intracranial or intraspinal bleeding
- Anuria
- Addison's disease

Severe or long standing hypernatraemia should be corrected gradually.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Not applicable.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cattle, horses, sheep, goats, pigs, dogs and cats

<u>Very rare</u> (<u><1 animal / 10,000 animals treated, including isolated reports</u>):	Thrombosis
<u>Undetermined frequency (cannot be estimated from the available data)</u>	Glycosuria ¹ , osmotic diuresis ¹

¹ If the product is administered at a rate in excess of 10 ml/kg bodyweight/hour. Please refer to sections 3.9 "Administration routes and dosage".

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

Incompatibilities with certain antibiotics (e.g. beta-lactam antibiotics, tetracyclines, sulfadiazine sodium) and heparin are recognised.

3.9 Administration routes and dosage

Intravenous use. Administer slowly via intravenous infusion.

For single use only.

This veterinary medicinal product should not be administered at a rate in excess of 10 ml/kg bodyweight/hour, otherwise glycosuria and osmotic diuresis may result.

Infusion rates should be calculated according to the presenting condition, bodyweight and degree of dehydration of the animal being treated.

The total fluid volume to be administered should consider existing deficits, maintenance requirements and ongoing losses.

IV fluids should be warmed up to body temperature prior to administration.

Maintain aseptic precautions throughout administration.

Do not use unless the solution is clear, free from visible particles, and the container is undamaged.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overperfusion can lead to overhydration, hypertension and extravascular fluid accumulation. Symptoms may include respiratory distress. In the case of overperfusion, reduce or cease fluid infusion and administer oxygen, diuretics and adjunctive treatment as necessary. Monitor respiration and heart rate, fluid output, electrolyte balance and blood glucose during administration.

The administration of excess glucose can lead to hyperglycaemia, glycosuria and polyuria.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

For administration only by a veterinarian.

3.12 Withdrawal periods

Cattle, horses, sheep, goats, pigs:

Meat and offal: Zero days

Cattle, horses, sheep, goats:

Milk: Zero hours

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QB05BA03

4.2 Pharmacodynamics

The veterinary medicinal product is an infusion used as a replacement source of water and glucose for animals that cannot be given rehydration fluids orally. It is isotonic on initial administration, (thereby avoiding causing osmotic shock to red blood cells), and the glucose is then metabolised to water, resulting in a net effect of administration of a hypotonic solution. The glucose can provide a transient source of nutrient and will aid in correction of hyperkalaemia. The calorie content is 17 kJ/g or 4 kcal/g of glucose.

4.3 Pharmacokinetics

Intravenous infusion ensures rapid distribution. The constituents of the infusion solution are metabolised and excreted through the same pathways as water and glucose derived from normal dietary sources.

5. PHARMACEUTICALS PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

The medicinal product is incompatible with calcium-disodium edetate, histamine diphosphate, sodium warfarin and sodium thiopental.

Glucose solutions should not be administered through the same infusion equipment simultaneously with, before, or after administration of blood, because of the possibility of pseudo-agglutination.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Shelf life after first opening the immediate packaging: Use immediately.

5.3 Special precautions for storage

Keep the bottle in the outer carton in order to protect from light.

5.4 Nature and composition of immediate packaging

Low density polyethylene bottles .

The additional closure cap on top of the sealed polyethylene container is made from high density polyethylene. Between the container and the closure cap an elastomeric latex free disk is placed.

Pack sizes:

Cardboard box containing one bottle of 100 ml

Cardboard box containing one bottle of 250 ml

Cardboard box containing one bottle of 500 ml

Cardboard box containing one bottle of 1000 ml

Cardboard box containing 20 bottles of 100 ml
Cardboard box containing 20 bottles of 250 ml
Cardboard box containing 10 bottles of 500 ml
Cardboard box containing 10 bottles of 1000 ml

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

B. Braun Melsungen AG

7. MARKETING AUTHORISATION NUMBER

Vm 03551/4002

8. DATE OF FIRST AUTHORISATION

03 May 2012

9. DATE OF LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

October 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.
Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Approved 06 January 2026

Gavin Hall